Roche's sweet spot: The $6B-$7B acquisition deal

Roche CFO Alan Hippe

Roche ($RHHBY) isn't likely to imitate its Big Pharma rivals who have been buying back their own shares to keep restive investors happy. Rather, top execs are on the lookout for new technologies that will make the pharma giant an even better competitor. And its sweet spot is the $6 billion to $7 billion mark as Roche stays in the hunt for buyouts--with a particular interest in gene sequencing. That's the bottom line for Chief Financial Officer Alan Hippe, who sat down with Bloomberg Industries analysts recently to discuss its deal strategy. Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.